|
Hopeful,
This is another wonderful article that is a must read for newly dx.
"who found that this marker outperforms tumor size, nodal status, age, and HER-2 as a prognostic factor."
This marker was discussed at the SABCS the speaker was Dr. Slamon. He stated the importance of this marker prior to treatment. There was a French onc. who was negative about the marker and stated that the test was not approved by our own FDA (at the time). I sat in my seat shaking my head, wondering how much longer do women have to face going to a bc onc. and the onc does not even know about TOPO 2...let alone where to have it tested? The seas are still divided on treatment, especially with the early stagers.
This article enforces the fact of testing and making treatment choices based on
scientific fact not fears. This is the essence of our site to provide articles such
as this to share the knowledge. Dr. Slamon tested me prior to treatment decisons, I tested negative
for the TOPO 2 marker - and I am also ER + therefore this article is of great importance to me.
I am praying that all have the benefit of testing.
Regards,
jean
__________________
Stage 1, Grade 1, 3/30/05
Lumpectomy 4/15/05 - 6MM IDC
Node Neg. (Sentinel node)
ER+ 90% / PR-, Her2+++ by FISH
Ki-67 40%
Arimidex 5/05
Radiation 32 trt, 5/30/05
Oncotype DX test 4/17/06, 31% high risk
TOPO 11 neg. 4/06
Stopped Arimidex 5/06
TCH 5/06, 6 treatments
Herceptin 5/06 - for 1 yr.
9/06 Completed chemo
Started Femara Sept. 2006
Last edited by Jean; 04-02-2008 at 06:23 AM..
|
Linear Mode
